Stocks › TAK
TAKEDA PHARMACEUTICAL CO LTD
TAK·NYSE·
Japan·USD
Japan·USD$18.10
+0.29 (+1.63%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
TAK
TAKEDA PHARMACEUTICAL CO LTD · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
TAKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of TAK by members of U.S. Congress · 19 on record · 1 in the last 12 months
Whale Activity
Position changes in TAK reported for 2026-06-30 by 8 tracked institutional filers
- Increased2
- New2
- Held1
- Decreased3
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 3.7M | $59.1M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 2.6M | $41.2M | decreased |
| D. E. Shaw & Co., Inc. | 2.0M | $32.9M | decreased |
| MILLENNIUM MANAGEMENT LLC | 1.1M | $16.8M | new |
| TWO SIGMA INVESTMENTS, LP | 485.7K | $7.8M | increased |
| CITADEL ADVISORS LLC | 168.1K | $2.7M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 123.4K | $2.0M | held |
| Point72 Asset Management, L.P. | 77.7K | $1.2M | new |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by TAK insiders, by quarter · Form 4
Recent Insider Transactions
30 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Duprey Lauren RusckowskiChief Transformation Officer | Sale | −34.5K | $18.54 | $640K | Sep 14, 2026 | Form 4 ↗ |
| Plump Andrew StewartPresident, R&D · Director | Sale | −116.2K | $18.49 | $2.1M | Sep 2, 2026 | Form 4 ↗ |
| Plump Andrew StewartPresident, R&D · Director | Sale | −19.7K | $18.49 | $363K | Aug 19, 2026 | Form 4 ↗ |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sale | −13.0K | $18.11 | $235K | Aug 18, 2026 | Form 4 ↗ |
| Shannon Elaine MaryPres., Global Supply & Quality | Sale | −20.4K | $17.55 | $357K | Aug 11, 2026 | Form 4 ↗ |
| Farajallah Awny Samaan BotrosChief Medical Officer | Sale | −14.0K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Ibrahim Ramy Riad AhmedPresident, PDT BU | Sale | −7,277 | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Pacheco Rhonda JanicePresident, U.S. Business Unit | Sale | −16.9K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Duprey Lauren RusckowskiChief Transformation Officer | Sale | −47.6K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Plump Andrew StewartPresident, R&D · Director | Sale | −165.4K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev | Sale | −23.0K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Bitetti Teresa MariePresident, OBU | Sale | −50.0K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Shannon Elaine MaryPres., Global Supply & Quality | Sale | −3,978 | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Ricci GabrieleChief Data & Tech. Officer | Sale | −25.1K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sale | −6,774 | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Kim Julie So-YoungPresident and CEO · Director | Sale | −89.1K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Platford Giles RichardPresident, IBU | Sale | −31.1K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Furney Natalie Anne MarieGlobal General Counsel | Sale | −30.9K | n/c | — | Aug 10, 2026 | Form 4 ↗ |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sale | −975 | $17.50 | $17K | Aug 10, 2026 | Form 4 ↗ |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sale | −33.6K | $17.51 | $589K | Aug 10, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding TAK · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| American Mutual Fund | 18.2M | $310.3M | 0.26% | Jul 31, 2026 |
| Capital Income Builder | 7.3M | $125.5M | 0.10% | Jul 31, 2026 |
| First Trust Value Line Dividend Index Fund First Trust Exchange-Traded Fund | 2.0M | $32.5M | 0.40% | Jun 30, 2026 |
| VanEck Pharmaceutical ETF VanEck ETF Trust | 1.6M | $25.3M | 2.87% | Jun 30, 2026 |
| Amplify CWP International Enhanced Dividend Income ETF Amplify ETF Trust | 886.8K | $16.4M | 1.60% | Mar 31, 2026 |
| Steward Values Enhanced International Fund Steward Funds Inc | 711.9K | $12.2M | 3.58% | Jul 31, 2026 |
| Mercer Non-US Core Equity Fund Mercer Funds | 586.1K | $9.4M | 0.20% | Jun 30, 2026 |
| Goldman Sachs Income Builder Fund GOLDMAN SACHS TRUST | 494.4K | $8.5M | 0.30% | Jul 31, 2026 |
| Avantis International Equity ETF American Century ETF Trust | 509.0K | $8.1M | 0.05% | May 31, 2026 |
| ActivePassive International Equity ETF Trust for Professional Managers | 170.1K | $2.7M | 0.26% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list TAK's shares (CUSIP 874060205), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming takeda pharmaceuticals as client
- TODD STRATEGY GROUPTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q2 · HCR, MMM, TRD$50K
Filing ↗ - AVENUE SOLUTIONSTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q2 · HCR$20K
Filing ↗ - TAKEDA PHARMACEUTICALS AMERICA, INC.TAKEDA PHARMACEUTICALS AMERICA INC · 2026 Q2 · BUD, MMM, HCR, TRD$610K
Filing ↗ - FARRAGUT PARTNERS LLPTAKEDA PHARMACEUTICALS AMERICA INC · 2026 Q2 · HCR$40K
Filing ↗ - TIBER CREEK GROUPTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q2 · MMM$50K
Filing ↗
Government Contracts
Federal awards to takeda pharmaceuticals · USAspending
$922KAwarded · 14 contracts on record
- Department of Veterans AffairsGAMMAGARD$58K
Oct 1, 2026 · ↗ - Department of Veterans AffairsTAKHZYRO 150 MG$38K
Aug 27, 2026 · ↗ - Department of Veterans AffairsTAKHZYRO 150 MG$0
Aug 27, 2026 · ↗ - Department of JusticeFY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER$551K
Apr 1, 2026 · ↗ - Department of Veterans AffairsLIVTENCITY 200 MG$19K
Aug 28, 2026 · ↗ - Department of Veterans AffairsGATTEX 5 MG$35K
Aug 25, 2026 · ↗ - Department of Veterans AffairsTAKHZYRO 150 MG$38K
Aug 20, 2026 · ↗ - Department of Veterans AffairsTAKHZYRO 150 MG$38K
Jul 31, 2026 · ↗
U.S. Patents
Recent USPTO applications naming TAKEDA PHARMACEUTICAL CO LTD
No USPTO patent applications found for TAKEDA PHARMACEUTICAL CO LTD.
Annual Financials
From TAK's 10-K filings · XBRL
No annual XBRL figures on record for TAK. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in TAK's price history.
Material Events (8-K)
Corporate events filed with the SEC
No 8-K filings on record.
About TAKEDA PHARMACEUTICAL CO LTD
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersTOKYO, Japan
SEC CIK0001395064 ↗